Applied Genetic Technologies Corporation (AGTC), a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases.
AGTC's lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. It also has completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, the company has proof-of-concept programs for other eye diseases, such as leber congenital amaurosis (type 2), and wet form of age-related macular degeneration. It has strategic collaboration agreements with SAFC Pharma; and 4D Molecular Therapeutics.
The company was founded in 1999 and is headquartered in Alachua, Florida.
December 13, 2018
RegMed Investors’ (RMi) pre-open: Biogen (BIIB) terminates their collaboration with Applied Genetic Technologies Corporation (AGTC) which dropped -$2.66 or -40.55% in the after and pre-market.
December 3, 2018
RegMed Investors’ (RMi) pre-open: up, up to possibly stay up
45 companies, 1 interpreter!
Insight, foresight and recommendation
Applied Genetics Technology Corporations (AGTC) In Q1/16, AGTC has clinical trial timing issues and spending woes – until clinical results are announced which are slow due to enrollments ...hold
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at firstname.lastname@example.org.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors